Aplos Medical (formerly CT Resources), a US-based company that develops next generation Gastroesophageal Reflux Disease (GERD) treatment, announced on Friday its successful first implantation of its Omega PF device.

The procedure was conducted at Dell Medical Center of University of Texas at Austin by Dr Tripp Buckley, an expert in GERD surgical treatments. The company said that the patient is doing well and is pleased with the outcome.

Aplos claims that the Omega PF device heralds a paradigm shift in GERD treatment. Being the first of its kind, the device seamlessly combines a dual-modality treatment; it not only controls reflux but ensures a natural, uncompromised swallowing process for the patient.

Aplos Medical president and CEO Dr Claude Tihon said, 'We are delighted by this monumental achievement, performed by Dr Buckley and his team. The simple Omega PF device is designed to mitigate common issues seen with current GERD treatments. We look forward to further progress being made toward our ultimate goal of benefitting millions of individuals suffering from acid reflux.'